3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Phase 3
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
1
Conditions
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Rectal Neoplasms
1
Pancreatic Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Lung Neoplasms
1
Liver Neoplasms
1
Gallbladder Neoplasms
1
Fatigue
1
Esophageal Neoplasms
1
ENT Cancer
1
Depressive Disorder, Major
1
Depression
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma
1
Breast Neoplasms
1
Bile Duct Neoplasms
1
Interventions
Paclitaxel
20
Gemcitabine
16
Dexamethasone
16
Bevacizumab
16
Docetaxel
15
Oxaliplatin
14
Cyclophosphamide
13
Carboplatin
12
Capecitabine
12
Sorafenib
11
Fluorouracil
11
Leucovorin
10
Cisplatin
10
pembrolizumab
9
Prednisone
9
Pemetrexed
9
Epoetin Alfa
9
venetoclax
8
atezolizumab
8
Fentanyl
8
Drug Therapy
8
Doxorubicin
8
Rivaroxaban
7
Rituximab
7
Darbepoetin alfa
7
Anastrozole
7
Panitumumab
6
Ondansetron
6
Morphine
6
Irinotecan
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Neoplasms
×
Escitalopram
×
Clear all
NCT04763135
2023-06-08
MIR-P
Hospices Civils de Lyon
Phase 3
Terminated
1 enrolled